<?xml version="1.0" encoding="UTF-8"?>
<ref id="B26-pharmaceutics-10-00039">
 <label>26.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Namanja</surname>
    <given-names>H.A.</given-names>
   </name>
   <name>
    <surname>Emmert</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Davis</surname>
    <given-names>D.A.</given-names>
   </name>
   <name>
    <surname>Campos</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Miller</surname>
    <given-names>D.S.</given-names>
   </name>
   <name>
    <surname>Hrycyna</surname>
    <given-names>C.A.</given-names>
   </name>
   <name>
    <surname>Chmielewski</surname>
    <given-names>J.</given-names>
   </name>
  </person-group>
  <article-title>Toward eradicating HIV reservoirs in the brain: Inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers</article-title>
  <source>J. Am. Chem. Soc.</source>
  <year>2012</year>
  <volume>134</volume>
  <fpage>2976</fpage>
  <lpage>2980</lpage>
  <pub-id pub-id-type="doi">10.1021/ja206867t</pub-id>
  <?supplied-pmid 21866921?>
  <pub-id pub-id-type="pmid">21866921</pub-id>
 </element-citation>
</ref>
